CVS Health Corporation has reported robust first-quarter results for 2026, with revenues rising to $100.4 billion and net income nearly hitting $3 billion, reflecting a 66% growth from the previous year. In response to these gains, the company raised its full-year guidance, prompting analysts to classify CVS as a 'Strong Buy' amid a year-to-date return surpassing 16%. Additionally, CVS’s strategic use of AI has led to significant operational efficiencies, contributing to a dramatic 66% cut in IT service costs.
“CVS Health · is aided by · revenue momentum in Health Services segment”
“CVS Health · has · stock price · $92.77”
“CVS Health · has · year-to-date returns · over 16%”
“CVS Health · posted · quarterly earnings · strong”
“CVS Health · posted · first-quarter results for 2026 · revenue rising by more than 6% to $100.4 billion”
“CVS Health · reported · net income · just under $3 billion”
“CVS Health · experienced · net income growth · up 66% from the prior-year period”
“CVS Health · has · medical benefit ratio · 84.6%”
“CVS Health · had · medical benefit ratio last year · 87.3%”
“CVS Health · trades at · forward price-to-earnings multiple · 13”
“CVS Health · yields · dividend · 2.9%”
“CVS Health · was not · one of the best stocks · true”
